Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
about
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsA Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz.Why Did I Stop? Barriers and Facilitators to Uptake and Adherence to ART in Option B+ HIV Care in Lilongwe, Malawi.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsPlasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African WomenThe impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenAssociation of NR1I2 gene polymorphisms and time of progression to AIDSCytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.Variation in CYP2A6 Activity and Personalized Medicine.Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability.
P2860
Q28069383-60DF5F76-8AC4-447E-8D4A-FB7890415149Q35802412-ED5C077A-AD18-4AFB-8BEC-A3A8BC0A2A72Q35931175-168C2FE6-B1DC-4878-86F8-34CF9C09E184Q36437792-877718F9-E829-464F-A5F7-3466A680247DQ36478066-F1EFC13C-7415-423B-9A00-22FFF30A443DQ36966640-F7FD7138-55EC-4F37-8FB4-5E1A06967461Q37030715-9A956437-467A-4B05-9373-AFE4E541AD79Q37705733-869C8780-7C67-480A-9EA5-615DCBC67DCCQ38987587-224E9BBC-29F6-4017-ACEB-970D0252A935Q40050910-11C291D3-F748-4C16-BF1A-C36FED0374C0Q40207726-B3FD0A60-BF76-4819-8D8B-824BA831F3F0Q41048998-6F48BEE5-06AC-4ABD-B076-0884B97DFBF4Q47163198-778A60BD-DF3C-42BC-9ADE-2B1AE03972C8Q49332317-82B89BDD-7427-4EE3-8024-E5D967D64286
P2860
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacogenetics of plasma efa ...... and children in South Africa.
@ast
Pharmacogenetics of plasma efa ...... and children in South Africa.
@en
type
label
Pharmacogenetics of plasma efa ...... and children in South Africa.
@ast
Pharmacogenetics of plasma efa ...... and children in South Africa.
@en
prefLabel
Pharmacogenetics of plasma efa ...... and children in South Africa.
@ast
Pharmacogenetics of plasma efa ...... and children in South Africa.
@en
P2093
P2860
P356
P1476
Pharmacogenetics of plasma efa ...... and children in South Africa.
@en
P2093
David W Haas
Joel A Dave
Naomi S Levitt
Paul D Leger
Peter J Smith
Phumla Z Sinxadi
P2860
P304
P356
10.1111/BCP.12590
P407
P577
2015-05-28T00:00:00Z